Experimental combined formulation containing retatrutide and the long-acting amylin analogue cagrilintide
PRODUCT PROFILE
Retatrutide + Cagrilintide
£59.99
Retatrutide + Cagrilintide is experimental combined formulation containing retatrutide and the long-acting amylin analogue cagrilintide. Researchers examine it in relation to parallel incretin, glucagon and amylin-pathway signalling in metabolic research.
Why it is distinct
It combines triple-receptor agonism with a separate amylin pathway, rather than adding another agent acting through the same receptor family.
- Evidence stageExperimental
- AvailabilityAvailable
- Batch recordPublished after verification
- DispatchConfirmed at checkout
PRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
Retatrutide + Cagrilintide is experimental combined formulation containing retatrutide and the long-acting amylin analogue cagrilintide. Researchers examine it in relation to parallel incretin, glucagon and amylin-pathway signalling in metabolic research.
Research focus+
Researchers are interested in whether the separate pathways could affect hunger, blood-sugar control and weight together. The exact combination has not been established as safe or effective.
How the mechanism differs+
Retatrutide activates GIP, GLP-1 and glucagon receptors, while cagrilintide acts through amylin-receptor pathways; the components therefore engage separate metabolic signalling systems.
Evidence and limitations+
Both components have individual human clinical research, but evidence for this exact combined formulation, ratio, compatibility, pharmacokinetics and safety is not established. It is not an authorised combined medicine.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Researchers are interested in whether the separate pathways could affect hunger, blood-sugar control and weight together. The exact combination has not been established as safe or effective.
Retatrutide activates GIP, GLP-1 and glucagon receptors, while cagrilintide acts through amylin-receptor pathways; the components therefore engage separate metabolic signalling systems.
It combines triple-receptor agonism with a separate amylin pathway, rather than adding another agent acting through the same receptor family.
Both components have individual human clinical research, but evidence for this exact combined formulation, ratio, compatibility, pharmacokinetics and safety is not established. It is not an authorised combined medicine.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Established
Tirzepatide
£79.0010 mgBatch file pendingDual incretin agonism distinguishes it from single-target semaglutide and triple-target retatrutide.
UnavailableAsk about availability -
Clinical research
Cagrilintide
£64.005 mgBatch file pendingTargets amylin biology, making it mechanistically distinct from every incretin agonist in the category.
UnavailableAsk about availability -
Established
Semaglutide
£69.005 mgBatch file pendingA single-pathway GLP-1 comparator rather than a dual or triple incretin agonist.
UnavailableAsk about availability -
Phase 2 clinical research
MOTS-c
£35.64Batch file pendingMOTS-c begins inside mitochondria and is studied for cell-wide energy adaptation, rather than directly targeting appetite receptors.
Available · 30 in stockAdd to basket